Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay020 in Advanced Solid Cancer
NCT02467569Phase 1Terminated
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hemay020 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Tianjin Hemay Biotech. Primary endpoints: Number of participants with adverse events, Observed maximum concentration of Hemay020 at Day 42 and 4 more. Started Jul 2015; status: terminated.
02
Drugs
hemay020
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02467569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467569.